FY2018 Earnings Estimate for Sientra Inc (SIEN) Issued By William Blair
Sientra Inc (NASDAQ:SIEN) – Analysts at William Blair reduced their FY2018 earnings estimates for shares of Sientra in a research report issued to clients and investors on Monday, November 12th. William Blair analyst M. Kaczor now forecasts that the medical instruments supplier will post earnings of ($2.98) per share for the year, down from their previous estimate of ($2.88). William Blair also issued estimates for Sientra’s Q4 2018 earnings at ($0.61) EPS, Q1 2019 earnings at ($0.56) EPS, Q2 2019 earnings at ($0.61) EPS, Q3 2019 earnings at ($0.58) EPS and FY2019 earnings at ($2.34) EPS.
A number of other research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, September 27th. BidaskClub downgraded shares of Sientra from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 21st. Stifel Nicolaus raised their price target on shares of Sientra from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Finally, Stephens restated a “buy” rating and issued a $30.00 price target on shares of Sientra in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Sientra currently has an average rating of “Buy” and a consensus price target of $22.50.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.05). The company had revenue of $16.90 million for the quarter, compared to analyst estimates of $16.66 million. Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. Sientra’s revenue was up 72.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.74) earnings per share.
In related news, CEO Jeffrey M. Nugent sold 1,852 shares of Sientra stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $24.90, for a total value of $46,114.80. Following the sale, the chief executive officer now directly owns 297,999 shares in the company, valued at approximately $7,420,175.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Timothy Haines sold 89,651 shares of Sientra stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the completion of the sale, the director now owns 37,662 shares in the company, valued at $811,992.72. The disclosure for this sale can be found here. Company insiders own 31.00% of the company’s stock.
Large investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co. NY bought a new stake in Sientra in the 2nd quarter valued at about $160,000. Accredited Investors Inc. bought a new stake in Sientra in the 3rd quarter valued at about $200,000. Commonwealth Equity Services LLC bought a new stake in Sientra in the 2nd quarter valued at about $210,000. MetLife Investment Advisors LLC bought a new stake in Sientra in the 2nd quarter valued at about $226,000. Finally, Tarbox Family Office Inc. lifted its position in Sientra by 595.3% in the 3rd quarter. Tarbox Family Office Inc. now owns 9,734 shares of the medical instruments supplier’s stock valued at $232,000 after purchasing an additional 8,334 shares during the last quarter. Hedge funds and other institutional investors own 88.39% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.